BioGaia Past Earnings Performance
Past criteria checks 2/6
BioGaia has been growing earnings at an average annual rate of 18.8%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 13% per year. BioGaia's return on equity is 17.1%, and it has net margins of 28.5%.
Key information
18.8%
Earnings growth rate
14.7%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 13.0% |
| Return on equity | 17.1% |
| Net Margin | 28.5% |
| Next Earnings Update | 23 Jul 2024 |
Recent past performance updates
Recent updates
BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
Apr 25
BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 09BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
Mar 26BioGaia (STO:BIOG B) Will Pay A Larger Dividend Than Last Year At SEK6.90
Mar 09BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90
Feb 24BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's
Feb 10Here's Why We Think BioGaia (STO:BIOG B) Might Deserve Your Attention Today
Nov 27Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Sep 13Does BioGaia (STO:BIOG B) Deserve A Spot On Your Watchlist?
Jun 02A Look At The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Apr 27Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?
Jan 14Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?
Aug 26Does This Valuation Of BioGaia AB (publ) (STO:BIOG B) Imply Investors Are Overpaying?
Jul 24Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Apr 02BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 21Need To Know: Analysts Are Much More Bullish On BioGaia AB (publ) (STO:BIOG B) Revenues
Feb 09BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's
Feb 07Some Shareholders May find It Hard To Increase BioGaia AB (publ)'s (STO:BIOG B) CEO Compensation This Year
Apr 29Key Things To Consider Before Buying BioGaia AB (publ) (STO:BIOG B) For Its Dividend
Mar 25The BioGaia (STO:BIOG B) Share Price Is Up 90% And Shareholders Are Holding On
Mar 04CEO & President Isabelle Valerie Ducellier Just Bought 8.2% More Shares In BioGaia AB (publ) (STO:BIOG B)
Feb 11Is BioGaia AB (publ)'s (STO:BIOG B) Latest Stock Performance A Reflection Of Its Financial Health?
Jan 26What Type Of Shareholders Own The Most Number of BioGaia AB (publ) (STO:BIOG B) Shares?
Jan 11
How Much Are BioGaia AB (publ) (STO:BIOG B) Insiders Taking Off The Table?
Dec 27Read This Before Buying BioGaia AB (publ) (STO:BIOG B) For Its Dividend
Dec 13BioGaia (STO:BIOG B) Shareholders Have Enjoyed A 57% Share Price Gain
Nov 28Revenue & Expenses Breakdown
How BioGaia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,300 | 371 | 415 | 113 |
| 31 Dec 23 | 1,297 | 365 | 403 | 107 |
| 30 Sep 23 | 1,273 | 437 | 399 | 110 |
| 30 Jun 23 | 1,213 | 415 | 387 | 111 |
| 31 Mar 23 | 1,186 | 413 | 375 | 101 |
| 31 Dec 22 | 1,104 | 374 | 361 | 107 |
| 30 Sep 22 | 1,036 | 273 | 341 | 106 |
| 30 Jun 22 | 952 | 246 | 302 | 103 |
| 31 Mar 22 | 867 | 222 | 262 | 103 |
| 31 Dec 21 | 785 | 196 | 231 | 105 |
| 30 Sep 21 | 767 | 196 | 206 | 105 |
| 30 Jun 21 | 725 | 164 | 198 | 105 |
| 31 Mar 21 | 766 | 188 | 197 | 104 |
| 31 Dec 20 | 747 | 180 | 198 | 105 |
| 30 Sep 20 | 767 | 194 | 203 | 99 |
| 30 Jun 20 | 802 | 211 | 210 | 105 |
| 31 Mar 20 | 780 | 193 | 213 | 106 |
| 31 Dec 19 | 768 | 187 | 209 | 105 |
| 30 Sep 19 | 770 | 192 | 200 | 111 |
| 30 Jun 19 | 778 | 205 | 195 | 110 |
| 31 Mar 19 | 756 | 207 | 192 | 107 |
| 31 Dec 18 | 742 | 215 | 181 | 100 |
| 30 Sep 18 | 702 | 206 | 173 | 94 |
| 30 Jun 18 | 675 | 197 | 166 | 86 |
| 31 Mar 18 | 631 | 181 | 153 | 78 |
| 31 Dec 17 | 615 | 181 | 149 | 76 |
| 30 Sep 17 | 584 | 179 | 143 | 70 |
| 30 Jun 17 | 562 | 172 | 139 | 69 |
| 31 Mar 17 | 542 | 163 | 132 | 67 |
| 31 Dec 16 | 535 | 160 | 129 | 64 |
| 30 Sep 16 | 500 | 138 | 118 | 57 |
| 30 Jun 16 | 480 | 129 | 114 | 53 |
| 31 Mar 16 | 478 | 130 | 111 | 52 |
| 31 Dec 15 | 483 | 138 | 112 | 53 |
| 30 Sep 15 | 500 | 130 | 115 | 60 |
| 30 Jun 15 | 474 | 119 | 114 | 59 |
| 31 Mar 15 | 432 | 97 | 115 | 58 |
| 31 Dec 14 | 482 | 147 | 107 | 54 |
| 30 Sep 14 | 451 | 146 | 102 | 46 |
| 30 Jun 14 | 433 | 145 | 98 | 43 |
| 31 Mar 14 | 426 | 142 | 93 | 42 |
| 31 Dec 13 | 316 | 62 | 94 | 41 |
| 30 Sep 13 | 298 | 60 | 92 | 41 |
Quality Earnings: BIOG B has high quality earnings.
Growing Profit Margin: BIOG B's current net profit margins (28.5%) are lower than last year (34.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOG B's earnings have grown by 18.8% per year over the past 5 years.
Accelerating Growth: BIOG B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BIOG B had negative earnings growth (-10.2%) over the past year, making it difficult to compare to the Biotechs industry average (2.9%).
Return on Equity
High ROE: BIOG B's Return on Equity (17.1%) is considered low.